Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Julie DeMartino"'
Autor:
Matthew Studham, Cristina Vazquez‐Mateo, Eileen Samy, Philipp Haselmayer, Aida Aydemir, P. Alexander Rolfe, Joan T. Merrill, Eric F. Morand, Julie DeMartino, Amy Kao, Robert Townsend
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 10, Pp 536-546 (2023)
Objective To use cell‐based gene signatures to identify patients with systemic lupus erythematous (SLE) in the phase II/III APRIL–SLE and phase IIb ADDRESS II trials most likely to respond to atacicept. Methods A published immune cell deconvoluti
Externí odkaz:
https://doaj.org/article/add9fe7b98494705a1bf88c69bce3eb1
Autor:
Thomas Clarke, Pan Du, Satyendra Kumar, Shinji L. Okitsu, Mark Schuette, Qi An, Jinyang Zhang, Evgeni Tzvetkov, Mark A. Jensen, Timothy B. Niewold, Elise M. N. Ferre, Julie Nardone, Michail S. Lionakis, Jaromir Vlach, Julie DeMartino, Andrew T. Bender
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Autoimmune diseases vary in the magnitude and diversity of autoantibody profiles, and these differences may be a consequence of different types of breaks in tolerance. Here, we compared the disparate autoimmune diseases autoimmune polyendocrinopathy
Externí odkaz:
https://doaj.org/article/e823a778e94642ba916ed495ae37f622
Autor:
Julie DeMartino, Jeff Kraines, Hugues Dolgos, Kerstin Kleinschmidt-Dörr, Robert Townsend, Anne Gigout, Flavie Moreau, Kyra J. Cowan
Publikováno v:
Drug Discovery Today. 25:1054-1064
Osteoarthritis (OA) is a common disease worldwide with large unmet medical needs. To bring innovative treatments to OA patients, we at Merck have implemented a comprehensive strategy for drug candidate evaluation. We have a clear framework for decisi
Autor:
Charles Wartchow, Julie DeMartino, David Robert Bolin, Gang Lu, Dan Li, Su Song, Chia Chi Sun, Lena Liang, Dinesh Srinivasan, Kuo-Sen Huang, Jaspreet Banga, Michelle Downing, Nader Fotouhi, Betsy J. Barnes, Cherrie D. Thompson, Hong Qian, Ann F. Hoffman, Seng-Lai Tan, Qin Guo, Yajuan Gu Qin, Jin Qiu, Francesca Milletti, Satwant K. Narula, Bharati Matta, Gang Chen, Margaret LaPan, Shannon Hamilton
Publikováno v:
Science Advances
The rational targeting of a transcription factor, interferon regulatory factor 5 (IRF5), inhibits downstream functions.
The transcription factor interferon regulatory factor 5 (IRF5) plays essential roles in pathogen-induced immunity downstream
The transcription factor interferon regulatory factor 5 (IRF5) plays essential roles in pathogen-induced immunity downstream
Autor:
Eileen Samy, Matthew Studham, P Chang, Amy H. Kao, Julie Demartino, P. Alexander Rolfe, Philipp Haselmayer, Robert M Townsend, David Wofsy
Publikováno v:
Poster Presentations.
Background: The Phase 2/3 APRIL-SLE study evaluated the safety and efficacy of atacicept, a dual inhibitor of the B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), in systemic lupus erythematosus (SLE). Objectives: The goal
Autor:
Eileen Samy, Julie Demartino, Robert M Townsend, P Chang, Amy H. Kao, David Wofsy, Philipp Haselmayer, Matthew Studham, Alex Rolfe
Publikováno v:
Abstracts.
Background The Phase II/III APRIL-SLE study evaluated the safety and efficacy of atacicept in systemic lupus erythematosus (SLE). The goal of this post-hoc analysis was to use cell-based gene signatures on the APRIL-SLE gene expression data to identi
Autor:
S. Riva, A. Paoletti, Julie Demartino, Philipp Haselmayer, Andrew Bender, V. Castagna, Pascal Schneider, R. Boggio, Eileen Samy, Y. Wu, E. Bertotti
Publikováno v:
FRIDAY, 15 JUNE 2018.
Background Atacicept is an antagonist of the B cell regulatory factors BLyS (B lymphocyte stimulator) and APRIL (a proliferation inducing ligand). It is capable of binding to all known conformations of BLyS and APRIL and is thus expected to modulate
Autor:
Kris A. Reedquist, John Woods, Julie DeMartino, Jay S. Fine, Satwant K. Narula, Man Wai Tang, Michael F Smith, L. M. Hartkamp, Inge E. van Es, Paul P. Tak
Publikováno v:
Annals of the rheumatic diseases, 74(8), 1603-1611. BMJ Publishing Group
Objectives Bruton9s tyrosine kinase (Btk) is required for B lymphocyte and myeloid cell contributions to pathology in murine models of arthritis. Here, we examined the potential contributions of synovial Btk expression and activation to inflammation
Autor:
Meera Ramanujam, Daigen Xu, Soo Min, John Woods, Jennifer Postelnek, Julia Ayala, Kai-Yeung Lau, Holly Hilton, Julie Hang, Yong Kim, Julie DeMartino, Rosario Garrido, Mario Giron, Stella Stefanova, Satwant K. Narula, Nena Dimaano, Toni Whittard, Natalie D. Keirstead, Alka Patel, Jacob LaStant, Paola Mina-Osorio
Publikováno v:
Arthritis & Rheumatism. 65:2380-2391
Objective Bruton's tyrosine kinase (BTK) plays a critical role in B cell development and function. We recently described a selective BTK inhibitor, RN486, that blocks B cell receptor (BCR) and Fcγ receptor signaling and is efficacious in animal mode
Autor:
Christopher Kitson, Xiaoyan Tang, Yonglin Ren, Qi Luo, Alan M. Holmes, Christopher P. Denton, Gaurav Tyagi, Rosario Garrido, Julie DeMartino, Christopher S. Stevenson, Cory M. Hogaboam, Subramanium Apparsundaram, Ruoqi Peng, David C. Budd, Maria E. Fuentes, Jeremy Deguzman, Jonathan E. Phillips, Carla M. T. Bauer
Publikováno v:
The American Journal of Pathology. 183:470-479
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of high unmet medical need. Although bromodomain (Brd) and extra terminal domain isoforms have recently been implicated in mediating inflammatory and oncologic indications, their roles in